Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B-DNA
genes	I-DNA
in	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B-protein
activity	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B-DNA
promoter	I-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O

The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	B-DNA
promoter-driven	I-DNA
beta-galactosidase	I-DNA
gene	I-DNA
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	B-protein
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O

A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-DNA
gene	I-DNA
with	O
an	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
,	O
results	O
in	O
beta-galactosidase	B-protein
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	B-cell_line
and	O
primary	B-cell_type
cells	I-cell_type
.	O

Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	I-protein
.	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Retroviral	NULL
Mediated	NULL
Transfer	NULL
and	NULL
Expression	NULL
of	NULL
Exogenous	NULL
Genes	NULL
in	NULL
Primary	NULL
Lymphoid	NULL
Cells	NULL
:	NULL
Assaying	NULL
for	NULL
a	NULL
Viral	NULL
Transactivator	NULL
Activity	NULL
in	NULL
Normal	NULL
and	NULL
Malignant	NULL
Cells	NULL
By	NULL
Roger	NULL
K.	NULL
Strair	NULL
,	NULL
Murray	NULL
Towle	NULL
,	NULL
Peter	NULL
W.	NULL
Heald	NULL
,	NULL
and	NULL
Brian	NULL
R.	NULL
Smith	NULL
In	NULL
this	NULL
report	NULL
we	NULL
describe	NULL
the	NULL
use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
to	NULL
characterize	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
exogenous	NULL
promoter	NULL
in	NULL
primary	NULL
cells	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
.	NULL

The	NULL
infection	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
cultured	NULL
and	NULL
primary	NULL
lymphoid	NULL
cells	NULL
with	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
a	NULL
histone	NULL
promoter-driven	NULL
3-galactosidase	NULL
gene	NULL
is	NULL
shown	NULL
to	NULL
result	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
B-galactosidase	NULL
in	NULL
50	NULL
%	NULL
to	NULL
100	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

A	NULL
similar	NULL
infection	NULL
with	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
the	NULL
B-galactosi-	NULL
ECOMBINANT	NULL
retroviruses	NULL
have	NULL
been	NULL
widely	NULL
used	NULL
for	NULL
the	NULL
transfer	NULL
and	NULL
analysis	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
.	NULL

The	NULL
availability	NULL
of	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
capable	NULL
of	NULL
producing	NULL
high	NULL
titers	NULL
of	NULL
defective	NULL
recombinant	NULL
retroviruses	NULL
has	NULL
made	NULL
it	NULL
possible	NULL
to	NULL
transfer	NULL
genes	NULL
efficiently	NULL
into	NULL
primary	NULL
cells	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
described	NULL
the	NULL
efficient	NULL
expression	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
in	NULL
primary	NULL
hematopoietic	NULL
cells	NULL
.	NULL
'	NULL

''	NULL
Furthermore	NULL
,	NULL
recombinant	NULL
retroviruses	NULL
have	NULL
been	NULL
used	NULL
to	NULL
express	NULL
genes	NULL
in	NULL
cells	NULL
derived	NULL
from	NULL
primary	NULL
lymphoid	NULL
,	NULL
hepatic	NULL
,	NULL
endothelial	NULL
,	NULL
and	NULL
fibroblast	NULL
cells	NULL
,	NULL
*	NULL
``	NULL
Recombinant	NULL
retroviruses	NULL
have	NULL
been	NULL
used	NULL
not	NULL
only	NULL
to	NULL
achieve	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
foreign	NULL
genes	NULL
,	NULL
but	NULL
also	NULL
to	NULL
analyze	NULL
promoter	NULL
function	NULL
in	NULL
cultured	NULL
cells	NULL
.	NULL

One	NULL
example	NULL
is	NULL
the	NULL
use	NULL
of	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
a	NULL
selectable	NULL
marker	NULL
gene	NULL
driven	NULL
by	NULL
a	NULL
adenovirus	NULL
5	NULL
E2	NULL
promoter	NULL
to	NULL
assess	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
selectable	NULL
marker	NULL
as	NULL
a	NULL
function	NULL
of	NULL
chromosomal	NULL
integration	NULL
site	NULL
and	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
adenovirus	NULL
5	NULL
Ela-encoded	NULL
``	NULL
transactivator	NULL
``	NULL
polypep-tides	NULL
.	NULL
``	NULL

Another	NULL
example	NULL
is	NULL
the	NULL
use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
containing	NULL
the	NULL
TnS	NULL
neo	NULL
gene	NULL
with	NULL
an	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
to	NULL
obtain	NULL
efficient	NULL
transfer	NULL
of	NULL
G418	NULL
resistance	NULL
to	NULL
cultured	NULL
cells	NULL
containing	NULL
Ela-encoded	NULL
polypeptides	NULL
whereas	NULL
cells	NULL
lacking	NULL
the	NULL
polypeptides	NULL
only	NULL
infrequently	NULL
became	NULL
G418	NULL
resistant	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
describe	NULL
a	NULL
model	NULL
system	NULL
that	NULL
extends	NULL
the	NULL
use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
to	NULL
the	NULL
study	NULL
of	NULL
promoter	NULL
function	NULL
in	NULL
primary	NULL
cells	NULL
obtained	NULL
from	NULL
normal	NULL
individuals	NULL
and	NULL
patients	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
often	NULL
difficult	NULL
to	NULL
transfect	NULL
DNA	NULL
efficiently	NULL
into	NULL
primary	NULL
cells	NULL
we	NULL
have	NULL
used	NULL
recombinant	NULL
retroviruses	NULL
to	NULL
transfer	NULL
marker	NULL
genes	NULL
containing	NULL
promoters	NULL
to	NULL
be	NULL
studied	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
transfection	NULL
,	NULL
the	NULL
use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
permits	NULL
gene	NULL
transfer	NULL
into	NULL
50	NULL
%	NULL
to	NULL
100	NULL
%	NULL
of	NULL
primary	NULL
lymphoid	NULL
cells	NULL
without	NULL
selection	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
we	NULL
used	NULL
the	NULL
Escherichia	NULL
coli	NULL
B-galactosidase	NULL
gene	NULL
as	NULL
a	NULL
marker	NULL
gene	NULL
because	NULL
it	NULL
can	NULL
be	NULL
quantitatively	NULL
assayed	NULL
on	NULL
a	NULL
single	NULL
cell	NULL
basis	NULL
,	NULL
allowing	NULL
the	NULL
assay	NULL
of	NULL
marker	NULL
gene	NULL
activity	NULL
in	NULL
subsets	NULL
of	NULL
cells	NULL
in	NULL
a	NULL
mixed	NULL
primary	NULL
cell	NULL
population	NULL
.	NULL

The	NULL
use	NULL
of	NULL
this	NULL
system	NULL
does	NULL
not	NULL
subject	NULL
the	NULL
primary	NULL
cells	NULL
to	NULL
either	NULL
prolonged	NULL
cell	NULL
culture	NULL
or	NULL
to	NULL
antibiotic	NULL
selection	NULL
,	NULL
circumstances	NULL
that	NULL
might	NULL
significantly	NULL
alter	NULL
the	NULL
biology	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

As	NULL
an	NULL
example	NULL
of	NULL
this	NULL
type	NULL
of	NULL
analysis	NULL
we	NULL
describe	NULL
the	NULL
use	NULL
of	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
a	NULL
B-galactosidase	NULL
gene	NULL
with	NULL
an	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
to	NULL
analyze	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
E2	NULL
promoter	NULL
in	NULL
lymphocytes	NULL
from	NULL
normal	NULL
donors	NULL
as	NULL
Blood	NULL
,	NULL
Vol	NULL
76	NULL
,	NULL
No	NULL
6	NULL
(	NULL
September	NULL
15	NULL
)	NULL
,	NULL
1990	NULL
:	NULL
pp	NULL
1201-1208	NULL
dase	NULL
gene	NULL
with	NULL
an	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
,	NULL
results	NULL
in	NULL
B-galactosidase	NULL
activity	NULL
in	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
cultured	NULL
and	NULL
primary	NULL
cells	NULL
.	NULL

Since	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
has	NULL
been	NULL
well	NULL
characterized	NULL
and	NULL
is	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
transactivators	NULL
encoded	NULL
by	NULL
many	NULL
viruses	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
promoter	NULL
in	NULL
specific	NULL
cell	NULL
types	NULL
is	NULL
discussed	NULL
in	NULL
reference	NULL
to	NULL
both	NULL
the	NULL
biology	NULL
of	NULL
the	NULL
cell	NULL
and	NULL
the	NULL
possible	NULL
presence	NULL
of	NULL
as	NULL
yet	NULL
undetected	NULL
viral	NULL
gene	NULL
products	NULL
.	NULL

©	NULL
1990	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

well	NULL
as	NULL
patients	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
lymphoproliferative	NULL
disorders	NULL
.	NULL

This	NULL
promoter	NULL
was	NULL
selected	NULL
because	NULL
it	NULL
is	NULL
highly	NULL
induc-ible	NULL
by	NULL
the	NULL
adenovirus	NULL
Ela-encoded	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
``	NULL
transactivator	NULL
``	NULL
polypeptides	NULL
encoded	NULL
by	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
viruses	NULL
including	NULL
adenoviruses	NULL
,	NULL
human	NULL
papilloma	NULL
virus	NULL
,	NULL
pseudorabies	NULL
virus	NULL
,	NULL
and	NULL
some	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
viruses	NULL
will	NULL
increase	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
driven	NULL
by	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
.	NULL

'*	NULL
``	NULL
In	NULL
the	NULL
absence	NULL
of	NULL
apparent	NULL
viral	NULL
transactivators	NULL
,	NULL
this	NULL
promoter	NULL
is	NULL
efficiently	NULL
expressed	NULL
in	NULL
undifferentiated	NULL
embryonic	NULL
cells	NULL
and	NULL
embryonal	NULL
carcinoma	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
Therefore	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
containing	NULL
this	NULL
promoter	NULL
is	NULL
dependent	NULL
on	NULL
transactivator	NULL
activity	NULL
that	NULL
is	NULL
either	NULL
encoded	NULL
by	NULL
viral	NULL
genes	NULL
or	NULL
tightly	NULL
regulated	NULL
cellular	NULL
genes	NULL
.	NULL

This	NULL
transactivator	NULL
activity	NULL
has	NULL
been	NULL
termed	NULL
``	NULL
Ela-like	NULL
``	NULL
activity	NULL
.	NULL
``	NULL

**	NULL
``	NULL
The	NULL
ability	NULL
to	NULL
assay	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
E2	NULL
promoter-driven	NULL
marker	NULL
genes	NULL
in	NULL
primary	NULL
cells	NULL
from	NULL
patients	NULL
allows	NULL
several	NULL
important	NULL
issues	NULL
related	NULL
to	NULL
the	NULL
biology	NULL
of	NULL
both	NULL
the	NULL
cells	NULL
and	NULL
the	NULL
E2	NULL
promoter	NULL
to	NULL
be	NULL
addressed	NULL
,	NULL
including	NULL
the	NULL
spectrum	NULL
of	NULL
cells	NULL
capable	NULL
of	NULL
expressing	NULL
the	NULL
E2	NULL
promoter	NULL
and	NULL
the	NULL
relationship	NULL
between	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
and	NULL
the	NULL
conditions	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

Perhaps	NULL
more	NULL
importantly	NULL
,	NULL
applying	NULL
this	NULL
assay	NULL
to	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
could	NULL
yield	NULL
useful	NULL
information	NULL
about	NULL
the	NULL
biology	NULL
of	NULL
these	NULL
disorders	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
same	NULL
technique	NULL
may	NULL
prove	NULL
useful	NULL
in	NULL
the	NULL
analysis	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
promoters	NULL
in	NULL
different	NULL
primary	NULL
cell	NULL
types	NULL
.	NULL

From	NULL
the	NULL
Departments	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
Laboratory	NULL
Medicine	NULL
and	NULL
Dermatology	NULL
;	NULL
Yale	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
New	NULL
Haven	NULL
,	NULL
CT	NULL
.	NULL

Submitted	NULL
February	NULL
15	NULL
,	NULL
1990	NULL
;	NULL
accepted	NULL
May	NULL
23	NULL
,	NULL
1990	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
(	NULL
Clinical	NULL
Oncology	NULL
Career	NULL
Development	NULL
Award	NULL
)	NULL
(	NULL
R.K.S	NULL
.	NULL
)	NULL

and	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
(	NULL
R29CA49407	NULL
)	NULL
.	NULL

B.R.S	NULL
.	NULL

is	NULL
a	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Roger	NULL
Strair	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Division	NULL
of	NULL
Medical	NULL
Oncology	NULL
,	NULL
Yale	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
333	NULL
Cedar	NULL
St	NULL
,	NULL
New	NULL
Haven	NULL
,	NULL
CT	NULL
06510	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1990	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/90/7606-0022	NULL
$	NULL
3.00/0	NULL
1201	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1202	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
.	NULL

All	NULL
restriction	NULL
and	NULL
DNA	NULL
modifying	NULL
enzymes	NULL
were	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
.	NULL

Production	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
.	NULL

-	NULL
Recombinant	NULL
retroviral	NULL
DNAs	NULL
were	NULL
constructed	NULL
as	NULL
modifications	NULL
of	NULL
previously	NULL
described	NULL
plasmids	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
``	NULL
Retroviruses	NULL
containing	NULL
the	NULL
E	NULL
coli	NULL
-galactosidase	NULL
gene	NULL
sequences	NULL
were	NULL
constructed	NULL
from	NULL
the	NULL
enhancer-deleted	NULL
HSG-neo	NULL
plasmid	NULL
described	NULL
by	NULL
Guild	NULL
et	NULL
al	NULL
.	NULL
``	NULL

''	NULL
HSG-neo	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
,	NULL
excising	NULL
the	NULL
Tn5	NULL
neo	NULL
gene	NULL
,	NULL
and	NULL
the	NULL
E	NULL
coli	NULL
B-galactosidase	NULL
gene	NULL
was	NULL
inserted	NULL
,	NULL
generating	NULL
a	NULL
retroviral	NULL
vector	NULL
plasmid	NULL
with	NULL
an	NULL
internal	NULL
histone	NULL
H4	NULL
promoter	NULL
5	NULL
'	NULL
to	NULL
the	NULL
E	NULL
coli	NULL
B-galactosidase	NULL
gene	NULL
.	NULL

To	NULL
generate	NULL
a	NULL
similar	NULL
plasmid	NULL
containing	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
,	NULL
HSG-neo	NULL
was	NULL
digested	NULL
with	NULL
Xho	NULL
I	NULL
and	NULL
BamHI	NULL
and	NULL
a	NULL
-galactosidase	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
E2	NULL
promoter	NULL
was	NULL
inserted	NULL
in	NULL
place	NULL
of	NULL
the	NULL
histone	NULL
H4	NULL
promoter-Tn5	NULL
neo	NULL
gene	NULL
.	NULL

The	NULL
resultant	NULL
retroviral	NULL
vector	NULL
plasmid	NULL
contains	NULL
an	NULL
internal	NULL
E2	NULL
promoter	NULL
5	NULL
'	NULL
to	NULL
the	NULL
B-galactosidase	NULL
gene	NULL
.	NULL

Production	NULL
of	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
encoding	NULL
the	NULL
human	NULL
CDS	NULL
antigen	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

To	NULL
generate	NULL
cell	NULL
lines	NULL
producing	NULL
recombinant	NULL
retroviruses	NULL
,	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
lines*	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
appropriate	NULL
plasmid	NULL
and	NULL
PSV	NULL
,	NULL
neo	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Colonies	NULL
were	NULL
generated	NULL
in	NULL
Dulbecco	NULL
's	NULL
Modified	NULL
Eagle	NULL
's	NULL
Medium	NULL
(	NULL
DMEM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
and	NULL
1.0	NULL
mg/mL	NULL
of	NULL
G418	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Individual	NULL
colonies	NULL
were	NULL
isolated	NULL
,	NULL
expanded	NULL
into	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
production	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
by	NULL
infection	NULL
of	NULL
NIH	NULL
3T3	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

``	NULL
``	NULL
*	NULL
Infection	NULL
of	NULL
lymphocytes	NULL
.	NULL

-	NULL
Human	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
by	NULL
ficoll-hypaque	NULL
density	NULL
gradient	NULL
separation	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
human	NULL
blood	NULL
.	NULL

Murine	NULL
spleen	NULL
cells	NULL
were	NULL
obtained	NULL
by	NULL
making	NULL
a	NULL
suspension	NULL
of	NULL
teased	NULL
spleen	NULL
cells	NULL
followed	NULL
by	NULL
ficoll-hypaque	NULL
density	NULL
gradient	NULL
separation	NULL
.	NULL

For	NULL
coculture	NULL
experiments	NULL
,	NULL
2	NULL
x	NULL
10°	NULL
lymphocytes	NULL
were	NULL
suspended	NULL
in	NULL
10	NULL
mL	NULL
of	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
2	NULL
ug/mL	NULL
of	NULL
polybrene	NULL
.	NULL

Medium	NULL
from	NULL
a	NULL
25	NULL
%	NULL
confluent	NULL
10-cm	NULL
plate	NULL
of	NULL
cells	NULL
producing	NULL
recombinant	NULL
retroviruses	NULL
was	NULL
removed	NULL
and	NULL
replaced	NULL
by	NULL
the	NULL
lymphocyte	NULL
suspension	NULL
.	NULL

After	NULL
48	NULL
hours	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
the	NULL
nonadherent	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Lymphocytes	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
marker	NULL
gene	NULL
expression	NULL
as	NULL
described	NULL
below	NULL
.	NULL

For	NULL
optimum	NULL
gene	NULL
transfer	NULL
efficiency	NULL
,	NULL
a	NULL
mixture	NULL
of	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
producing	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
were	NULL
used	NULL
.	NULL

Ninety-six	NULL
hours	NULL
before	NULL
infection	NULL
,	NULL
the	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
producing	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
of	NULL
interest	NULL
were	NULL
cocultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
ug/ml	NULL
of	NULL
polybrene	NULL
.	NULL

The	NULL
night	NULL
before	NULL
the	NULL
lymphocyte	NULL
infection	NULL
this	NULL
combined	NULL
amphotropic-ecotropic	NULL
packaging	NULL
cell	NULL
line	NULL
was	NULL
split	NULL
1:15	NULL
into	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

The	NULL
following	NULL
day	NULL
the	NULL
lymphocyte	NULL
infection	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
human	NULL
lymphocytes	NULL
were	NULL
propagated	NULL
for	NULL
an	NULL
additional	NULL
14	NULL
days	NULL
in	NULL
culture	NULL
using	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
and	NULL
1	NULL
%	NULL
conditioned	NULL
medium	NULL
(	NULL
obtained	NULL
as	NULL
supernatants	NULL
from	NULL
normal	NULL
human	NULL
lymphocytes	NULL
stimulated	NULL
for	NULL
72	NULL
hours	NULL
with	NULL
5	NULL
ug/ml	NULL
of	NULL
phytohemag-glutinin	NULL
[	NULL
PHA	NULL
]	NULL
)	NULL
.	NULL

Assay	NULL
of	NULL
gene	NULL
transfer	NULL
.	NULL

To	NULL
detect	NULL
B-galactosidase	NULL
activity	NULL
in	NULL
lymphocytes	NULL
by	NULL
light	NULL
microscopy	NULL
,	NULL
infected	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
DMEM	NULL
and	NULL
fixed	NULL
and	NULL
stained	NULL
as	NULL
described	NULL
by	NULL
Price	NULL
et	NULL
al	NULL
.	NULL
``	NULL

The	NULL
final	NULL
staining	NULL
solution	NULL
contained	NULL
5	NULL
mmol/L	NULL
of	NULL
potassium	NULL
ferricyanide	NULL
,	NULL
5	NULL
mmol/L	NULL
of	NULL
potassium	NULL
ferrocyanide	NULL
,	NULL
1	NULL
mmol/L	NULL
of	NULL
MgCl	NULL
,	NULL
and	NULL
1	NULL
mg/mL	NULL
of	NULL
5-bromo-4-chloro-3-indolyl-3-p-galactopyranoside	NULL
(	NULL
X-gal	NULL
)	NULL
.	NULL

Detection	NULL
of	NULL
B-galactosidase	NULL
activity	NULL
by	NULL
fluorescence	NULL
and	NULL
flow	NULL
cytometry	NULL
was	NULL
accomplished	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
procedure	NULL
described	NULL
by	NULL
Nolan	NULL
et	NULL
al	NULL
.	NULL
``	NULL

Lymphocytes	NULL
were	NULL
gently	NULL
removed	NULL
from	NULL
the	NULL
plate	NULL
and	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
pH	NULL
7.3	NULL
STRAIR	NULL
ET	NULL
AL	NULL
with	NULL
10	NULL
mmol/L	NULL
Hepes	NULL
and	NULL
4	NULL
%	NULL
FCS	NULL
(	NULL
SM	NULL
)	NULL
.	NULL

Approximately	NULL
10°	NULL
cells	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
0.1	NULL
mL	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
5-mL	NULL
tube	NULL
at	NULL
37°C	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

An	NULL
equal	NULL
volume	NULL
of	NULL
37°C	NULL
prewarmed	NULL
2	NULL
mmol/L	NULL
fluorescein-	NULL
(	NULL
FDG	NULL
)	NULL
(	NULL
Molecular	NULL
Probes	NULL
,	NULL
Eugene	NULL
,	NULL
OR	NULL
)	NULL
in	NULL
water	NULL
was	NULL
added	NULL
,	NULL
thoroughly	NULL
mixed	NULL
with	NULL
cells	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
minute	NULL
.	NULL

The	NULL
incubation	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
1.8	NULL
mL	NULL
of	NULL
ice	NULL
cold	NULL
SM	NULL
.	NULL

Cells	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACstar	NULL
or	NULL
FACscan	NULL
instrument	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Assay	NULL
of	NULL
murine	NULL
lymphocytes	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
CD5	NULL
antigen	NULL
was	NULL
accomplished	NULL
by	NULL
labeling	NULL
with	NULL
phycoerythrin-conjugated	NULL
mouse	NULL
anti-human	NULL
CDS	NULL
(	NULL
Leu	NULL
1	NULL
,	NULL
Becton-Dickinson	NULL
)	NULL
followed	NULL
by	NULL
cell	NULL
sorter	NULL
analysis	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Control	NULL
labeling	NULL
with	NULL
a	NULL
murine	NULL
phycoerythrin-conjugated	NULL
Ig	NULL
isotype-matched	NULL
irrelevant	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
was	NULL
performed	NULL
simultaneously	NULL
.	NULL

Dual	NULL
labeling	NULL
of	NULL
human	NULL
lymphocytes	NULL
was	NULL
performed	NULL
by	NULL
first	NULL
staining	NULL
for	NULL
FDG	NULL
activity	NULL
followed	NULL
by	NULL
direct	NULL
immunofluorescence	NULL
surface	NULL
labeling	NULL
with	NULL
either	NULL
phycoerythrin-conjugated	NULL
anti-CD4	NULL
,	NULL
anti-CD8	NULL
,	NULL
or	NULL
anti-CDS	NULL
(	NULL
Becton-Dickinson	NULL
)	NULL
.	NULL

For	NULL
analysis	NULL
all	NULL
cells	NULL
labeled	NULL
for	NULL
the	NULL
particular	NULL
surface	NULL
marker	NULL
were	NULL
gated	NULL
and	NULL
a	NULL
single	NULL
parameter	NULL
histogram	NULL
of	NULL
green	NULL
fluorescence	NULL
(	NULL
FDG	NULL
staining	NULL
)	NULL
obtained	NULL
.	NULL

Clinical	NULL
specimens	NULL
.	NULL

-	NULL
Lymphoid	NULL
cells	NULL
from	NULL
normal	NULL
human	NULL
donors	NULL
and	NULL
patients	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
lymphoproliferative	NULL
disorders	NULL
were	NULL
obtained	NULL
from	NULL
blood	NULL
samples	NULL
and	NULL
processed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
three	NULL
patients	NULL
with	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
ALL	NULL
)	NULL
all	NULL
had	NULL
at	NULL
least	NULL
80	NULL
%	NULL
circulating	NULL
malignant	NULL
cells	NULL
that	NULL
were	NULL
of	NULL
pre-B-cell	NULL
phenotype	NULL
(	NULL
CALLA*	NULL
)	NULL
.	NULL

The	NULL
patients	NULL
with	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
CLL	NULL
)	NULL
had	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
circulating	NULL
CDS*	NULL
monoclonal	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
patient	NULL
with	NULL
Sezary	NULL
cell	NULL
leukemia	NULL
had	NULL
90	NULL
%	NULL
circulating	NULL
malignant	NULL
CD4*	NULL
cells	NULL
.	NULL

This	NULL
patient	NULL
had	NULL
a	NULL
prolonged	NULL
history	NULL
of	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
with	NULL
typical	NULL
morphologic	NULL
features	NULL
in	NULL
blood	NULL
as	NULL
well	NULL
as	NULL
skin	NULL
.	NULL

RESULTS	NULL
Efficient	NULL
infection	NULL
of	NULL
primary	NULL
lymphocytes	NULL
.	NULL

-	NULL
As	NULL
a	NULL
prerequisite	NULL
to	NULL
the	NULL
analysis	NULL
of	NULL
E2	NULL
promoter	NULL
activity	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
define	NULL
conditions	NULL
that	NULL
would	NULL
allow	NULL
efficient	NULL
gene	NULL
transfer	NULL
into	NULL
primary	NULL
lymphoid	NULL
cells	NULL
.	NULL

Recombinant	NULL
retroviruses	NULL
were	NULL
used	NULL
because	NULL
the	NULL
ability	NULL
to	NULL
efficiently	NULL
express	NULL
exogenous	NULL
genes	NULL
in	NULL
other	NULL
primary	NULL
cell	NULL
types	NULL
has	NULL
been	NULL
demonstrated	NULL
.	NULL

To	NULL
obtain	NULL
a	NULL
quantitative	NULL
estimate	NULL
of	NULL
the	NULL
efficiency	NULL
of	NULL
retroviral-mediated	NULL
infection	NULL
,	NULL
the	NULL
transfer	NULL
of	NULL
two	NULL
marker	NULL
genes	NULL
was	NULL
analyzed	NULL
.	NULL

The	NULL
first	NULL
marker	NULL
gene	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
``	NULL
and	NULL
uses	NULL
an	NULL
enhancer-deleted	NULL
recombinant	NULL
retrovirus	NULL
``	NULL
containing	NULL
the	NULL
histone	NULL
H4	NULL
promoter	NULL
immediately	NULL
5	NULL
to	NULL
the	NULL
human	NULL
CDS	NULL
antigen	NULL
mRNA	NULL
sequences	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
infection	NULL
murine	NULL
lymphocytes	NULL
are	NULL
assayed	NULL
for	NULL
human	NULL
CD5	NULL
expression	NULL
by	NULL
staining	NULL
with	NULL
anti-human	NULL
CD5	NULL
antibody	NULL
and	NULL
analysis	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
second	NULL
marker	NULL
system	NULL
uses	NULL
an	NULL
enhancer-deleted	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
an	NULL
internal	NULL
histone	NULL
H4	NULL
promoter	NULL
immediately	NULL
5	NULL
'	NULL
to	NULL
-galactosidase	NULL
mRNA	NULL
sequences	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
infection	NULL
lymphocytes	NULL
are	NULL
assayed	NULL
for	NULL
-galactosidase	NULL
activity	NULL
by	NULL
staining	NULL
with	NULL
5-bromo-4-chloro-3-indolyl-3-p-galactopyranoside	NULL
(	NULL
X-gal	NULL
)	NULL
and	NULL
visualization	NULL
by	NULL
light	NULL
microscopy	NULL
or	NULL
by	NULL
staining	NULL
with	NULL
FDG	NULL
followed	NULL
by	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

Using	NULL
each	NULL
of	NULL
these	NULL
recombinant	NULL
retroviruses	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
establish	NULL
conditions	NULL
that	NULL
allow	NULL
the	NULL
transfer	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
marker	NULL
gene	NULL
into	NULL
50	NULL
%	NULL
to	NULL
100	NULL
%	NULL
of	NULL
primary	NULL
murine	NULL
or	NULL
human	NULL
lymphocytes	NULL
.	NULL

Optimal	NULL
conditions	NULL
of	NULL
gene	NULL
transfer	NULL
were	NULL
obtained	NULL
by	NULL
coculturing	NULL
primary	NULL
lymphocytes	NULL
for	NULL
48	NULL
hours	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
ecotropic	NULL
and	NULL
amphotropic	NULL
cell	NULL
lines	NULL
producing	NULL
high	NULL
titers	NULL
(	NULL
>	NULL
10'/mL	NULL
)	NULL
of	NULL
the	NULL
recombinant	NULL
retrovi-	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

GENE	NULL
TRANSFER	NULL
INTO	NULL
LYMPHOID	NULL
CELLS	NULL
rus	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
in	NULL
culture	NULL
the	NULL
lymphocytes	NULL
were	NULL
assayed	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
marker	NULL
gene	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
did	NULL
not	NULL
improve	NULL
the	NULL
efficiency	NULL
of	NULL
gene	NULL
transfer	NULL
using	NULL
these	NULL
conditions	NULL
.	NULL

Figure	NULL
1	NULL
demonstrates	NULL
the	NULL
efficient	NULL
gene	NULL
transfer	NULL
obtained	NULL
under	NULL
these	NULL
conditions	NULL
.	NULL

To	NULL
assure	NULL
that	NULL
the	NULL
nonadherent	NULL
cells	NULL
being	NULL
assayed	NULL
were	NULL
lymphocytes	NULL
rather	NULL
than	NULL
cells	NULL
from	NULL
the	NULL
packaging	NULL
cell	NULL
line	NULL
,	NULL
human	NULL
cells	NULL
were	NULL
cocultured	NULL
with	NULL
either	NULL
the	NULL
mixed	NULL
ecotropic-amphotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
producing	NULL
the	NULL
3-galactosidase	NULL
virus	NULL
or	NULL
an	NULL
ecotropic	NULL
cell	NULL
line	NULL
producing	NULL
the	NULL
3-galactosidase	NULL
virus	NULL
.	NULL

The	NULL
harvested	NULL
cells	NULL
were	NULL
stained	NULL
simultaneously	NULL
with	NULL
both	NULL
FDG	NULL
(	NULL
green	NULL
fluorescence	NULL
)	NULL
and	NULL
phycoerythrin-conjugated	NULL
mouse	NULL
anti-human	NULL
CDS	NULL
,	NULL
CD4	NULL
,	NULL
or	NULL
CD8	NULL
MoAbs	NULL
(	NULL
red	NULL
fluorescence	NULL
)	NULL
.	NULL

Approximately	NULL
70	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
being	NULL
assayed	NULL
were	NULL
CDS	NULL
®	NULL
cells	NULL
and	NULL
analysis	NULL
of	NULL
the	NULL
CDS*	NULL
population	NULL
as	NULL
well	NULL
as	NULL
the	NULL
analysis	NULL
of	NULL
CD4®*	NULL
and	NULL
CD8*	NULL
cells	NULL
demonstrated	NULL
expression	NULL
of	NULL
-galactosidase	NULL
in	NULL
each	NULL
of	NULL
these	NULL
subsets	NULL
of	NULL
cells	NULL
after	NULL
coculture	NULL
with	NULL
the	NULL
mixed	NULL
amphotropic-ecotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
expression	NULL
is	NULL
seen	NULL
in	NULL
the	NULL
cells	NULL
cocultured	NULL
with	NULL
the	NULL
ecotropic	NULL
packaging	NULL
line	NULL
Control	NULL
/	NULL
infected	NULL
Control	NULL
/	NULL
infected	NULL
/	NULL
10°	NULL
10	NULL
'	NULL
10	NULL
%	NULL
10°	NULL
10+	NULL
1203	NULL
itself	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
being	NULL
assayed	NULL
are	NULL
T	NULL
cells	NULL
and	NULL
that	NULL
both	NULL
the	NULL
CD4	NULL
and	NULL
CD8	NULL
populations	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
the	NULL
B-galactosidase	NULL
retrovirus	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
short-term	NULL
stability	NULL
of	NULL
expression	NULL
,	NULL
infected	NULL
lymphocytes	NULL
were	NULL
cultured	NULL
for	NULL
14	NULL
additional	NULL
days	NULL
in	NULL
mitogen-conditioned	NULL
medium	NULL
and	NULL
assayed	NULL
for	NULL
B-galactosidase	NULL
expression	NULL
using	NULL
FDG	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
3	NULL
B-galactosidase	NULL
expression	NULL
is	NULL
observed	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
cells	NULL
at	NULL
17	NULL
days	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
difficult	NULL
to	NULL
determine	NULL
how	NULL
many	NULL
of	NULL
the	NULL
cells	NULL
expressing	NULL
B-galactosidase	NULL
3	NULL
days	NULL
after	NULL
infection	NULL
have	NULL
been	NULL
stimulated	NULL
by	NULL
the	NULL
mitogen-conditioned	NULL
medium	NULL
and	NULL
continue	NULL
to	NULL
express	NULL
-galactosidase	NULL
for	NULL
an	NULL
additional	NULL
14	NULL
days	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
at	NULL
least	NULL
some	NULL
of	NULL
the	NULL
cells	NULL
staining	NULL
shortly	NULL
after	NULL
infection	NULL
are	NULL
capable	NULL
of	NULL
stable	NULL
expression	NULL
of	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
after	NULL
mitogen	NULL
stimulation	NULL
.	NULL

Recombinant	NULL
retroviruses	NULL
containing	NULL
the	NULL
E	NULL
Coli	NULL
B-galactosidase	NULL
gene	NULL
with	NULL
an	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
detect	NULL
cell	NULL
lines	NULL
with	NULL
``	NULL
Ela-like	NULL
``	NULL
activity	NULL
.	NULL

-	NULL
An	NULL
additional	NULL
recombinant	NULL
retrovirus	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
an	NULL
enhancer-deleted	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
an	NULL
internal	NULL
adenovirus	NULL
E2	NULL
©	NULL
.	NULL

@	NULL
.	NULL

«	NULL
S	NULL
Fig	NULL
1	NULL
.	NULL

Efficient	NULL
retroviral-mediated	NULL
infection	NULL
and	NULL
expression	NULL
in	NULL
primary	NULL
lymphocytes	NULL
.	NULL

Primary	NULL
murine	NULL
(	NULL
panel	NULL
a	NULL
)	NULL
or	NULL
human	NULL
(	NULL
panels	NULL
b	NULL
and	NULL
c	NULL
)	NULL
lymphocytes	NULL
infected	NULL
with	NULL
recombinant	NULL
retroviruses	NULL
.	NULL

Primary	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
,	NULL
infected	NULL
,	NULL
and	NULL
assayed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Murine	NULL
lymphocytes	NULL
infected	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
CD5	NULL
mRNA	NULL
sequences	NULL
were	NULL
stained	NULL
with	NULL
a	NULL
phycoerythrin-conjugated	NULL
anti-human	NULL
CD5	NULL
MoAb	NULL
and	NULL
assayed	NULL
for	NULL
immunofluorescence	NULL
using	NULL
flow	NULL
cytometry	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Cell	NULL
number	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
ordinate	NULL
and	NULL
relative	NULL
immunofluorescence	NULL
in	NULL
arbitrary	NULL
units	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
abscissa	NULL
.	NULL

Light	NULL
lines	NULL
are	NULL
mock	NULL
infected	NULL
lymphocytes	NULL
and	NULL
dark	NULL
lines	NULL
are	NULL
infected	NULL
lymphocytes	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Human	NULL
lymphocytes	NULL
infected	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
H4	NULL
promoter	NULL
adj	NULL
to	NULL
the	NULL
3-gal	NULL
id	NULL
mRNA	NULL
seq	NULL
Staining	NULL
of	NULL
inf	NULL
d	NULL
and	NULL
control	NULL
lymphocytes	NULL
with	NULL
FDG	NULL
followed	NULL
by	NULL
fluorescence	NULL
assay	NULL
using	NULL
FDG	NULL
.	NULL

Cell	NULL
number	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
ordinate	NULL
and	NULL
relative	NULL
fluorescence	NULL
in	NULL
arbitrary	NULL
units	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
abscissa	NULL
.	NULL

Light	NULL
lines	NULL
are	NULL
mock	NULL
infected	NULL
lymphocytes	NULL
and	NULL
dark	NULL
lines	NULL
are	NULL
infected	NULL
lymphocytes	NULL
.	NULL

(	NULL
c	NULL
)	NULL
X-gal	NULL
staining	NULL
of	NULL
control	NULL
(	NULL
above	NULL
)	NULL
and	NULL
lymphocytes	NULL
infected	NULL
with	NULL
the	NULL
virus	NULL
ining	NULL
the	NULL
H4	NULL
pr	NULL
adj	NULL
to	NULL
the	NULL
3-gal	NULL
idase	NULL
mRNA	NULL
seq	NULL
(	NULL
above	NULL
)	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1204	NULL
STRAIR	NULL
ET	NULL
AL	NULL
300	NULL
300	NULL
CD5	NULL
+	NULL
CELL	NULL
NUMBER	NULL
0	NULL
10°	NULL
_	NULL
10	NULL
!	NULL

102	NULL
109	NULL
CD4+	NULL
300	NULL
CD8	NULL
+	NULL
10	NULL
!	NULL

102	NULL
109	NULL
_	NULL
o	NULL
!	NULL

102	NULL
FL1	NULL
Fig	NULL
2	NULL
.	NULL

Human	NULL
lymphocytes	NULL
were	NULL
cocultured	NULL
with	NULL
either	NULL
the	NULL
mixed	NULL
amphotropic-ecotropic	NULL
packaging	NULL
lines	NULL
producing	NULL
the	NULL
H4	NULL
promoter-3-galactosidase	NULL
gene	NULL
or	NULL
with	NULL
the	NULL
ecotropic	NULL
line	NULL
producing	NULL
the	NULL
same	NULL
retrovirus	NULL
.	NULL

Nonadherent	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
48	NULL
hours	NULL
and	NULL
after	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
the	NULL
lymphocytes	NULL
were	NULL
stained	NULL
with	NULL
both	NULL
FDG	NULL
and	NULL
phycoerythrin-conjugated	NULL
mouse	NULL
anti-human	NULL
CDS	NULL
,	NULL
CD4	NULL
,	NULL
or	NULL
CD8	NULL
MoAbs	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
cell	NULL
populations	NULL
was	NULL
analyzed	NULL
separately	NULL
using	NULL
dual	NULL
label	NULL
flow	NULL
cytometry	NULL
.	NULL

(	NULL
A	NULL
)	NULL
CD5*	NULL
cells	NULL
analyzed	NULL
for	NULL
fluorescence	NULL
after	NULL
incubation	NULL
with	NULL
FDG	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD4*	NULL
cells	NULL
.	NULL

(	NULL
C	NULL
)	NULL
A	NULL
similar	NULL
analysis	NULL
with	NULL
CD8*	NULL
cells	NULL
.	NULL

Light	NULL
lines	NULL
,	NULL
cells	NULL
cocultured	NULL
with	NULL
the	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
line	NULL
;	NULL
dark	NULL
lines	NULL
,	NULL
cells	NULL
cocultured	NULL
with	NULL
the	NULL
mixed	NULL
amphotropic-ecotropic	NULL
packaging	NULL
cell	NULL
line	NULL
.	NULL

Cell	NULL
number	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
ordinate	NULL
and	NULL
relative	NULL
fluorescence	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
abscissa	NULL
.	NULL

promoter	NULL
adjacent	NULL
to	NULL
the	NULL
B-galactosidase	NULL
sequences	NULL
.	NULL

Packaging	NULL
cell	NULL
lines	NULL
producing	NULL
high	NULL
titers	NULL
of	NULL
each	NULL
of	NULL
these	NULL
viruses	NULL
were	NULL
generated	NULL
and	NULL
used	NULL
for	NULL
infections	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
two	NULL
retroviruses	NULL
encoding	NULL
B-galactosidase	NULL
(	NULL
driven	NULL
by	NULL
either	NULL
a	NULL
histone	NULL
H4	NULL
promoter	NULL
or	NULL
an	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
)	NULL
were	NULL
used	NULL
to	NULL
infect	NULL
NIH	NULL
3T3	NULL
cells	NULL
and	NULL
NIH	NULL
3T3	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
Ela-encoded	NULL
289	NULL
amino	NULL
acid	NULL
``	NULL
transactivator	NULL
``	NULL
300	NULL
CELL	NULL
NUMBER	NULL
0	NULL
L	NULL
|	NULL
10°	NULL
-	NULL
ao	NULL
!	NULL

104	NULL
_	NULL
10	NULL
%	NULL
FL1	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Human	NULL
lymphocytes	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
retrovirus	NULL
containing	NULL
the	NULL
histone	NULL
H4	NULL
gene	NULL
.	NULL

Nonadherent	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
placed	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
1	NULL
%	NULL
conditioned	NULL
medium	NULL
obtained	NULL
by	NULL
PHA	NULL
treatment	NULL
of	NULL
normal	NULL
lymphocytes	NULL
.	NULL

Medium	NULL
was	NULL
changed	NULL
every	NULL
3	NULL
days	NULL
until	NULL
day	NULL
14	NULL
when	NULL
the	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
,	NULL
stained	NULL
with	NULL
FDG	NULL
,	NULL
and	NULL
analyzed	NULL
using	NULL
flow	NULL
cytometry	NULL
.	NULL

Cell	NULL
number	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
ordinate	NULL
and	NULL
relative	NULL
fluorescence	NULL
is	NULL
displayed	NULL
on	NULL
the	NULL
abscissa	NULL
.	NULL

Light	NULL
line	NULL
,	NULL
mock	NULL
infected	NULL
lymphocytes	NULL
;	NULL
dark	NULL
line	NULL
,	NULL
infected	NULL
lymphocytes	NULL
.	NULL

10+	NULL
polypeptide	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
infection	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
-galactosidase	NULL
activity	NULL
using	NULL
the	NULL
fluorescence	NULL
cytometric	NULL
assay	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
4	NULL
,	NULL
wild	NULL
type	NULL
3T3	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
the	NULL
E2	NULL
promoter	NULL
contain	NULL
little	NULL
if	NULL
any	NULL
B-galactosidase	NULL
activity	NULL
whereas	NULL
3T3	NULL
cells	NULL
containing	NULL
the	NULL
Ela	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
have	NULL
a	NULL
higher	NULL
amount	NULL
of	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
the	NULL
histone	NULL
H4	NULL
promoter	NULL
adjacent	NULL
to	NULL
the	NULL
-galactosidase	NULL
cDNA	NULL
results	NULL
in	NULL
high	NULL
levels	NULL
of	NULL
B-galactosidase	NULL
activity	NULL
in	NULL
either	NULL
cell	NULL
type	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
demonstrates	NULL
preferential	NULL
expression	NULL
of	NULL
the	NULL
virus	NULL
in	NULL
cells	NULL
with	NULL
``	NULL
Ela	NULL
activity	NULL
.	NULL
``	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
E2	NULL
promoter	NULL
to	NULL
express	NULL
in	NULL
the	NULL
cells	NULL
containing	NULL
the	NULL
E1	NULL
A-encoded	NULL
polypeptide	NULL
assures	NULL
that	NULL
the	NULL
titer	NULL
of	NULL
the	NULL
viral	NULL
preparation	NULL
is	NULL
sufficiently	NULL
high	NULL
to	NULL
achieve	NULL
infection	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
3T3	NULL
cells	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
titration	NULL
of	NULL
the	NULL
histone	NULL
promoter	NULL
containing	NULL
virus	NULL
and	NULL
the	NULL
E2	NULL
promoter	NULL
containing	NULL
virus	NULL
on	NULL
3T	NULL
3	NULL
cells	NULL
containing	NULL
the	NULL
Ela-encoded	NULL
polypeptide	NULL
and	NULL
on	NULL
a	NULL
human	NULL
cell	NULL
line	NULL
,	NULL
C8166	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
indicates	NULL
nearly	NULL
identical	NULL
titers	NULL
of	NULL
the	NULL
two	NULL
packaging	NULL
cell	NULL
lines	NULL
.	NULL

A	NULL
similar	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
coculture	NULL
of	NULL
several	NULL
cell	NULL
lines	NULL
with	NULL
packaging	NULL
cell	NULL
lines	NULL
producing	NULL
each	NULL
of	NULL
the	NULL
recombinant	NULL
retroviruses	NULL
described	NULL
above	NULL
.	NULL

Figure	NULL
5	NULL
shows	NULL
an	NULL
analysis	NULL
of	NULL
Jurkatt	NULL
,	NULL
PBALL	NULL
,	NULL
and	NULL
C8166	NULL
cells	NULL
cocultured	NULL
with	NULL
the	NULL
packaging	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
E2-B-galactosidase	NULL
virus	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
Jurkatt	NULL
and	NULL
PBALL	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
retrovirus	NULL
containing	NULL
the	NULL
E2	NULL
promoter	NULL
do	NULL
not	NULL
express	NULL
B-galactosidase	NULL
activity	NULL
whereas	NULL
B-galactosidase	NULL
activity	NULL
is	NULL
easily	NULL
detected	NULL
in	NULL
C8166	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
E2	NULL
virus	NULL
.	NULL

Use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
to	NULL
detect	NULL
``	NULL
El	NULL
A-like	NULL
``	NULL
activity	NULL
in	NULL
normal	NULL
and	NULL
abnormal	NULL
primary	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
to	NULL
transfer	NULL
and	NULL
analyze	NULL
the	NULL
AB-galactosidase	NULL
constructs	NULL
with	NULL
recombinant	NULL
retroviruses	NULL
allows	NULL
the	NULL
applica-	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

GENE	NULL
TRANSFER	NULL
INTO	NULL
LYMPHOID	NULL
CELLS	NULL
A	NULL
3T3	NULL
B	NULL
3T3-EIA	NULL
L	NULL
O	NULL
|	NULL
2	NULL
.	NULL

3	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
Infection	NULL
of	NULL
NIH	NULL
3T3	NULL
cells	NULL
and	NULL
NIH	NULL
3T3	NULL
cells	NULL
constitutively	NULL
expressing	NULL
the	NULL
E1A	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
with	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
the	NULL
A-galactosidase	NULL
mRNA	NULL
sequences	NULL
adjacent	NULL
to	NULL
the	NULL
adenovirus	NULL
E2	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Wild	NULL
type	NULL
3T3	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
.	NULL

Virus	NULL
for	NULL
these	NULL
infections	NULL
was	NULL
obtained	NULL
by	NULL
harvesting	NULL
supernatants	NULL
from	NULL
cocultures	NULL
of	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
packaging	NULL
cell	NULL
lines	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
the	NULL
supernatants	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

Seventy-two	NULL
hours	NULL
after	NULL
infection	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
B-galactosidase	NULL
activity	NULL
using	NULL
the	NULL
FDG	NULL
assay	NULL
.	NULL

Light	NULL
lines	NULL
,	NULL
control	NULL
cells	NULL
;	NULL
heavy	NULL
lines	NULL
,	NULL
infected	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
same	NULL
experiment	NULL
performed	NULL
with	NULL
NIH	NULL
3T3	NULL
cells	NULL
constitutively	NULL
expressing	NULL
the	NULL
E1A	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
.	NULL
``	NULL

4	NULL
tion	NULL
of	NULL
these	NULL
assays	NULL
to	NULL
primary	NULL
cells	NULL
.	NULL

Figure	NULL
6	NULL
shows	NULL
that	NULL
primary	NULL
lymphocytes	NULL
obtained	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
contain	NULL
B-galactosidase	NULL
activity	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
histone	NULL
promoter	NULL
but	NULL
not	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
E2	NULL
promoter	NULL
.	NULL

Similar	NULL
analyses	NULL
were	NULL
performed	NULL
on	NULL
primary	NULL
lymphoid	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Fig	NULL
6	NULL
also	NULL
shows	NULL
that	NULL
malignant	NULL
lymphoid	NULL
cells	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
ALL	NULL
do	NULL
not	NULL
express	NULL
@	NULL
-galactosidase	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
E2-containing	NULL
virus	NULL
whereas	NULL
malignant	NULL
lymphocytes	NULL
from	NULL
a	NULL
1205	NULL
patient	NULL
with	NULL
Sezary	NULL
syndrome	NULL
do	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
both	NULL
patients	NULL
express	NULL
B-galactosidase	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
histone	NULL
promoter	NULL
implies	NULL
that	NULL
the	NULL
differences	NULL
are	NULL
not	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
infection	NULL
efficiency	NULL
.	NULL

Before	NULL
the	NULL
description	NULL
of	NULL
the	NULL
fluorescence	NULL
assay	NULL
for	NULL
B-galactosidase	NULL
activity	NULL
,	NULL
similar	NULL
infections	NULL
were	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
two	NULL
patients	NULL
with	NULL
ALL	NULL
and	NULL
three	NULL
patients	NULL
with	NULL
CLL	NULL
.	NULL

However	NULL
,	NULL
detection	NULL
of	NULL
-galactosidase	NULL
activity	NULL
in	NULL
those	NULL
studies	NULL
was	NULL
done	NULL
by	NULL
staining	NULL
with	NULL
5-bromo-4-chloro-3-	NULL
A	NULL
Jurkatt	NULL
10	NULL
Fig	NULL
5	NULL
.	NULL

Cell	NULL
lines	NULL
assayed	NULL
after	NULL
coculture	NULL
with	NULL
packaging	NULL
cell	NULL
lines	NULL
producing	NULL
the	NULL
E2-	NULL
#	NULL
-galactosidase	NULL
virus	NULL
.	NULL

The	NULL
indicated	NULL
cell	NULL
lines	NULL
were	NULL
cocultured	NULL
with	NULL
producer	NULL
cell	NULL
lines	NULL
as	NULL
described	NULL
in	NULL
the	NULL
text	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
infection	NULL
the	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
B-galactosidase	NULL
activity	NULL
using	NULL
the	NULL
FDG	NULL
assay	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Light	NULL
line	NULL
,	NULL
control	NULL
cells	NULL
;	NULL
heavy	NULL
line	NULL
,	NULL
infected	NULL
cells	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1206	NULL
A	NULL
LYMPHS	NULL
E2	NULL
H4	NULL
/	NULL
Control	NULL
L	NULL
1	NULL
L	NULL
0°	NULL
0	NULL
!	NULL

102	NULL
10°	NULL
10+	NULL
|	NULL
B	NULL
Control	NULL
ALL	NULL
/*	NULL
|	NULL
(	NULL
E2	NULL
|	NULL
H4	NULL
/*	NULL
10°	NULL
o	NULL
``	NULL
10	NULL
%	NULL
10°	NULL
104	NULL
10°	NULL
o	NULL
``	NULL
102	NULL
10°	NULL
10°	NULL
Fig	NULL
6	NULL
.	NULL

Primary	NULL
lymphoid	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
a	NULL
normal	NULL
donor	NULL
(	NULL
A	NULL
)	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
ALL	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
a	NULL
patient	NULL
with	NULL
Sezary	NULL
syndrome	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
divided	NULL
into	NULL
three	NULL
aliquots	NULL
,	NULL
mock	NULL
infected	NULL
(	NULL
control	NULL
)	NULL
,	NULL
and	NULL
cocultured	NULL
with	NULL
the	NULL
E2	NULL
promoter-driven	NULL
B-galactosidase	NULL
virus	NULL
(	NULL
E2	NULL
)	NULL
or	NULL
the	NULL
histone	NULL
promoter-driven	NULL
B-galactosidase	NULL
virus	NULL
(	NULL
H4	NULL
)	NULL
.	NULL

Three	NULL
days	NULL
after	NULL
infection	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
-galactosidase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

indolyl-8-p-galactopyranoside	NULL
(	NULL
X-gal	NULL
)	NULL
followed	NULL
by	NULL
microscopic	NULL
detection	NULL
of	NULL
blue	NULL
cells	NULL
.	NULL

Using	NULL
this	NULL
less	NULL
efficient	NULL
B-galactosidase	NULL
detection	NULL
system	NULL
,	NULL
3T	NULL
3	NULL
cells	NULL
expressing	NULL
the	NULL
Ela	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
infected	NULL
with	NULL
the	NULL
E2	NULL
virus	NULL
and	NULL
C8166	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
E2	NULL
virus	NULL
contained	NULL
detectable	NULL
tosidase	NULL
activity	NULL
whereas	NULL
B-galactosidase	NULL
activity	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
lymphocytes	NULL
from	NULL
three	NULL
patients	NULL
with	NULL
CLL	NULL
and	NULL
two	NULL
patients	NULL
with	NULL
ALL	NULL
infected	NULL
with	NULL
the	NULL
E2	NULL
virus	NULL
.	NULL

STRAIR	NULL
ET	NULL
AL	NULL
DISCUSSION	NULL
We	NULL
have	NULL
described	NULL
a	NULL
system	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
promoter	NULL
function	NULL
in	NULL
primary	NULL
cells	NULL
.	NULL

The	NULL
use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
allows	NULL
efficient	NULL
transfer	NULL
of	NULL
the	NULL
promoter	NULL
of	NULL
interest	NULL
into	NULL
the	NULL
primary	NULL
cells	NULL
.	NULL

The	NULL
use	NULL
of	NULL
B-galactosidase	NULL
as	NULL
a	NULL
marker	NULL
gene	NULL
allows	NULL
the	NULL
quantitative	NULL
detection	NULL
of	NULL
gene	NULL
expression	NULL
on	NULL
a	NULL
cellular	NULL
basis	NULL
.	NULL

Hence	NULL
,	NULL
promoter	NULL
function	NULL
can	NULL
be	NULL
assayed	NULL
in	NULL
primary	NULL
cells	NULL
without	NULL
the	NULL
need	NULL
for	NULL
either	NULL
transfection	NULL
of	NULL
DNA	NULL
or	NULL
prolonged	NULL
propagation	NULL
of	NULL
the	NULL
primary	NULL
cells	NULL
in	NULL
culture	NULL
.	NULL

The	NULL
avoidance	NULL
of	NULL
transfection	NULL
is	NULL
important	NULL
since	NULL
it	NULL
is	NULL
often	NULL
an	NULL
inefficient	NULL
means	NULL
of	NULL
DNA	NULL
transfer	NULL
into	NULL
primary	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
to	NULL
assay	NULL
the	NULL
marker	NULL
gene	NULL
on	NULL
a	NULL
single	NULL
cell	NULL
basis	NULL
is	NULL
also	NULL
important	NULL
since	NULL
it	NULL
allows	NULL
the	NULL
rapid	NULL
detection	NULL
of	NULL
gene	NULL
expression	NULL
using	NULL
a	NULL
fluorescence	NULL
assay	NULL
without	NULL
the	NULL
need	NULL
for	NULL
selection	NULL
.	NULL

Another	NULL
advantage	NULL
to	NULL
this	NULL
assay	NULL
is	NULL
the	NULL
ability	NULL
to	NULL
perform	NULL
dual	NULL
fluorescence	NULL
should	NULL
it	NULL
be	NULL
necessary	NULL
to	NULL
assay	NULL
promoter	NULL
function	NULL
in	NULL
subpopulations	NULL
of	NULL
the	NULL
primary	NULL
cells	NULL
.	NULL

Recombinant	NULL
retroviruses	NULL
containing	NULL
a	NULL
@	NULL
-galactosidase	NULL
gene	NULL
with	NULL
the	NULL
E2	NULL
promoter	NULL
were	NULL
used	NULL
to	NULL
study	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
E2	NULL
promoter	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cultured	NULL
and	NULL
primary	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
that	NULL
in	NULL
3T3	NULL
cells	NULL
,	NULL
T-cell	NULL
lines	NULL
such	NULL
as	NULL
Jurkatt	NULL
and	NULL
PBALL	NULL
,	NULL
primary	NULL
normal	NULL
lymphoid	NULL
cells	NULL
,	NULL
and	NULL
primary	NULL
malignant	NULL
lymphoid	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
CLL	NULL
and	NULL
ALL	NULL
,	NULL
the	NULL
E2	NULL
promoter-driven	NULL
B-galactosidase	NULL
gene	NULL
is	NULL
not	NULL
expressed	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
3T	NULL
3	NULL
cells	NULL
containing	NULL
the	NULL
Ela-encoded	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
,	NULL
C8166	NULL
cells	NULL
,	NULL
and	NULL
malignant	NULL
lymphoid	NULL
cells	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
Sezary	NULL
syndrome	NULL
,	NULL
a	NULL
malignant	NULL
T-cell	NULL
lymphoma	NULL
,	NULL
do	NULL
express	NULL
an	NULL
E2	NULL
promoter-driven	NULL
B-galactosidase	NULL
gene	NULL
.	NULL

Interestingly	NULL
,	NULL
C8166	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
express	NULL
the	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
transactivator	NULL
polypeptide	NULL
.	NULL
``	NULL

In	NULL
patients	NULL
with	NULL
lymphoproliferative	NULL
disorders	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
express	NULL
the	NULL
E2	NULL
promoter	NULL
within	NULL
72	NULL
hours	NULL
of	NULL
obtaining	NULL
fresh	NULL
blood	NULL
samples	NULL
.	NULL

Control	NULL
experiments	NULL
with	NULL
a	NULL
recombinant	NULL
retrovirus	NULL
containing	NULL
a	NULL
histone	NULL
promoter-driven	NULL
B-galactosidase	NULL
gene	NULL
indicated	NULL
that	NULL
the	NULL
cells	NULL
could	NULL
be	NULL
infected	NULL
with	NULL
recombinant	NULL
retroviruses	NULL
and	NULL
express	NULL
B-galactosidase	NULL
so	NULL
that	NULL
failure	NULL
to	NULL
detect	NULL
-galactosidase	NULL
expression	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
virus	NULL
containing	NULL
the	NULL
E2	NULL
promoter	NULL
is	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
activity	NULL
of	NULL
this	NULL
promoter	NULL
in	NULL
the	NULL
cell	NULL
type	NULL
studied	NULL
.	NULL

The	NULL
E2	NULL
promoter	NULL
has	NULL
been	NULL
well	NULL
characterized	NULL
by	NULL
many	NULL
investigators	NULL
.	NULL

Protein	NULL
binding	NULL
sites	NULL
,	NULL
including	NULL
a	NULL
site	NULL
for	NULL
a	NULL
cyclic	NULL
adenosine	NULL
monophosphate	NULL
(	NULL
cAMP	NULL
)	NULL
-responsive	NULL
binding	NULL
protein	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
relationship	NULL
between	NULL
these	NULL
binding	NULL
proteins	NULL
and	NULL
inducibility	NULL
by	NULL
the	NULL
Ela	NULL
289	NULL
amino	NULL
acid	NULL
polypeptide	NULL
has	NULL
been	NULL
studied	NULL
.	NULL

However	NULL
,	NULL
the	NULL
exact	NULL
mechanisms	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
this	NULL
promoter	NULL
remain	NULL
unclear	NULL
.	NULL

Several	NULL
unrelated	NULL
viruses	NULL
also	NULL
produce	NULL
transactivator	NULL
proteins	NULL
capable	NULL
of	NULL
increasing	NULL
expression	NULL
from	NULL
E2	NULL
promoter-driven	NULL
genes	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
HTLV-II	NULL
encoded	NULL
transactivator	NULL
polypeptide	NULL
to	NULL
activate	NULL
the	NULL
E2	NULL
promoter	NULL
has	NULL
been	NULL
described	NULL
before	NULL
``	NULL
``	NULL
and	NULL
is	NULL
supported	NULL
by	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
;	NULL
E2	NULL
promoter-driven	NULL
B-galactosidase	NULL
activity	NULL
can	NULL
be	NULL
readily	NULL
detected	NULL
in	NULL
C8166	NULL
cells	NULL
,	NULL
which	NULL
contain	NULL
the	NULL
related	NULL
HTLV-I	NULL
encoded	NULL
transactivator	NULL
.	NULL

Other	NULL
viruses	NULL
reported	NULL
to	NULL
produce	NULL
genes	NULL
capable	NULL
of	NULL
increasing	NULL
expression	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

GENE	NULL
TRANSFER	NULL
INTO	NULL
LYMPHOID	NULL
CELLS	NULL
from	NULL
the	NULL
E2	NULL
promoter	NULL
include	NULL
such	NULL
diverse	NULL
viruses	NULL
as	NULL
:	NULL
SV40	NULL
,	NULL
human	NULL
papilloma	NULL
viruses	NULL
,	NULL
pseudorabies	NULL
virus	NULL
,	NULL
and	NULL
HTLV-II	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
viral	NULL
transactivators	NULL
the	NULL
E2	NULL
promoter	NULL
is	NULL
generally	NULL
inactive	NULL
.	NULL

One	NULL
notable	NULL
exception	NULL
is	NULL
the	NULL
high	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
E2	NULL
promoter-driven	NULL
genes	NULL
in	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
or	NULL
early	NULL
embryos	NULL
.	NULL

In	NULL
these	NULL
cell	NULL
types	NULL
the	NULL
ability	NULL
to	NULL
express	NULL
genes	NULL
driven	NULL
by	NULL
the	NULL
E2	NULL
promoter	NULL
is	NULL
tightly	NULL
regulated	NULL
:	NULL
neither	NULL
differentiated	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
nor	NULL
mature	NULL
embryos	NULL
will	NULL
express	NULL
E2	NULL
promoter-driven	NULL
genes	NULL
.	NULL
``	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
expression	NULL
of	NULL
genes	NULL
containing	NULL
an	NULL
E2	NULL
promoter	NULL
indicates	NULL
either	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
viral	NULL
transactivator	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
regulated	NULL
developmental	NULL
stage	NULL
of	NULL
the	NULL
cell	NULL
.	NULL

DNA	NULL
extracted	NULL
from	NULL
the	NULL
lymphoid	NULL
cells	NULL
of	NULL
the	NULL
patient	NULL
with	NULL
Sezary	NULL
syndrome	NULL
did	NULL
not	NULL
contain	NULL
nucleotide	NULL
sequences	NULL
complementary	NULL
to	NULL
adenovirus	NULL
5	NULL
,	NULL
human	NULL
papilloma	NULL
virus	NULL
16	NULL
or	NULL
18	NULL
,	NULL
or	NULL
HTLV-I	NULL
or	NULL
-II	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interpreted	NULL
in	NULL
this	NULL
light	NULL
the	NULL
-galactosidase	NULL
activity	NULL
seen	NULL
in	NULL
the	NULL
patient	NULL
's	NULL
Sezary	NULL
cells	NULL
after	NULL
infection	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
the	NULL
E2	NULL
virus	NULL
may	NULL
be	NULL
indicative	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
as	NULL
yet	NULL
uncharacterized	NULL
viral	NULL
transactivator	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
Sezary	NULL
cells	NULL
from	NULL
this	NULL
patient	NULL
may	NULL
be	NULL
in	NULL
a	NULL
unique	NULL
stage	NULL
of	NULL
lymphoid	NULL
differentiation	NULL
that	NULL
allows	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
E2	NULL
virus	NULL
.	NULL

In	NULL
either	NULL
case	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
E2	NULL
promoter	NULL
in	NULL
these	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
other	NULL
,	NULL
primary	NULL
lymphoid	NULL
cells	NULL
may	NULL
provide	NULL
interesting	NULL
insights	NULL
into	NULL
the	NULL
biology	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Conceivably	NULL
the	NULL
dependence	NULL
of	NULL
the	NULL
1207	NULL
E2	NULL
promoter	NULL
on	NULL
transactivation	NULL
may	NULL
allow	NULL
the	NULL
widespread	NULL
use	NULL
of	NULL
the	NULL
E2	NULL
virus	NULL
to	NULL
detect	NULL
and	NULL
isolate	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
viruses	NULL
present	NULL
in	NULL
pathologic	NULL
tissues	NULL
.	NULL

Such	NULL
an	NULL
assay	NULL
would	NULL
require	NULL
neither	NULL
nucleic	NULL
acid	NULL
sequence	NULL
information	NULL
nor	NULL
immu-nologic	NULL
reagents	NULL
.	NULL

Attempts	NULL
to	NULL
isolate	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
E2	NULL
promoter	NULL
in	NULL
these	NULL
cells	NULL
as	NULL
well	NULL
a	NULL
comprehensive	NULL
analysis	NULL
of	NULL
E2	NULL
promoter	NULL
activity	NULL
in	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
primary	NULL
malignant	NULL
cells	NULL
are	NULL
currently	NULL
underway	NULL
.	NULL

As	NULL
a	NULL
prerequisite	NULL
to	NULL
these	NULL
studies	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
demonstrate	NULL
the	NULL
efficient	NULL
transfer	NULL
of	NULL
exogenous	NULL
genes	NULL
into	NULL
primary	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
indicate	NULL
that	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
achieve	NULL
infection	NULL
and	NULL
expression	NULL
of	NULL
50	NULL
%	NULL
to	NULL
100	NULL
%	NULL
of	NULL
primary	NULL
normal	NULL
or	NULL
malignant	NULL
lymphocytes	NULL
with	NULL
the	NULL
use	NULL
of	NULL
an	NULL
assay	NULL
system	NULL
that	NULL
allows	NULL
the	NULL
rapid	NULL
detection	NULL
of	NULL
the	NULL
transferred	NULL
gene	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
the	NULL
stability	NULL
of	NULL
expression	NULL
,	NULL
B-galactosidase	NULL
activity	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
that	NULL
proliferate	NULL
in	NULL
culture	NULL
for	NULL
17	NULL
days	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
difficult	NULL
to	NULL
ascertain	NULL
the	NULL
stability	NULL
of	NULL
B-galactosidase	NULL
for	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
infected	NULL
and	NULL
expressing	NULL
3-galactosidase	NULL
at	NULL
day	NULL
3	NULL
,	NULL
it	NULL
does	NULL
appear	NULL
that	NULL
those	NULL
cells	NULL
that	NULL
respond	NULL
to	NULL
mitogen-conditioned	NULL
medium	NULL
are	NULL
capable	NULL
of	NULL
stable	NULL
-galactosidase	NULL
expression	NULL
for	NULL
at	NULL
least	NULL
2	NULL
weeks	NULL
.	NULL

The	NULL
further	NULL
characterization	NULL
of	NULL
this	NULL
system	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
feasibility	NULL
of	NULL
using	NULL
infected	NULL
lymphocytes	NULL
to	NULL
express	NULL
genes	NULL
in	NULL
vivo	NULL
is	NULL
currently	NULL
underway	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Keller	NULL
G	NULL
,	NULL
Paige	NULL
C	NULL
,	NULL
Gilboa	NULL
E	NULL
,	NULL
Wagner	NULL
F	NULL
:	NULL
Expression	NULL
of	NULL
a	NULL
foreign	NULL
gene	NULL
in	NULL
myeloid	NULL
and	NULL
lymphoid	NULL
cells	NULL
derived	NULL
from	NULL
multipotent	NULL
hematopoietic	NULL
precursors	NULL
.	NULL

Nature	NULL
318:149	NULL
,	NULL
1985	NULL
2	NULL
.	NULL

Dzierzak	NULL
EA	NULL
,	NULL
Pappayannopoulou	NULL
T	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Lineage	NULL
specific	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
beta-globin	NULL
gene	NULL
in	NULL
mouse	NULL
bone	NULL
marrow	NULL
transplantation	NULL
recipients	NULL
reconstituted	NULL
with	NULL
retroviral	NULL
trans-duced	NULL
stem	NULL
cells	NULL
.	NULL

Nature	NULL
331:35	NULL
,	NULL
1988	NULL
3	NULL
.	NULL

Hock	NULL
RA	NULL
,	NULL
Millet	NULL
AD	NULL
:	NULL
Retroviral	NULL
mediated	NULL
transfer	NULL
and	NULL
expression	NULL
of	NULL
drug	NULL
resistance	NULL
genes	NULL
in	NULL
human	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
.	NULL

Nature	NULL
320:275	NULL
,	NULL
1985	NULL
4	NULL
.	NULL

Lim	NULL
B	NULL
,	NULL
Williams	NULL
DA	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
Retroviral	NULL
mediated	NULL
gene	NULL
transfer	NULL
of	NULL
human	NULL
ADA	NULL
:	NULL
Expression	NULL
of	NULL
functional	NULL
enzyme	NULL
in	NULL
murine	NULL
hematopoietic	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
7:3459	NULL
,	NULL
1987	NULL
5	NULL
.	NULL

Stead	NULL
RB	NULL
,	NULL
Kwok	NULL
WW	NULL
,	NULL
Storb	NULL
R	NULL
,	NULL
Miller	NULL
AD	NULL
:	NULL
Canine	NULL
model	NULL
for	NULL
gene	NULL
therapy	NULL
:	NULL
Inefficient	NULL
expression	NULL
in	NULL
dogs	NULL
reconstituted	NULL
with	NULL
autologous	NULL
marrow	NULL
infected	NULL
with	NULL
recombinant	NULL
retroviruses	NULL
.	NULL

Blood	NULL
71:741	NULL
,	NULL
1988	NULL
6	NULL
.	NULL

Morgan	NULL
JR	NULL
,	NULL
Barrandon	NULL
Y	NULL
,	NULL
Green	NULL
H	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Expression	NULL
of	NULL
exogenous	NULL
growth	NULL
hormone	NULL
by	NULL
transplantation	NULL
of	NULL
human	NULL
epidermal	NULL
cells	NULL
.	NULL

Science	NULL
237:1476	NULL
,	NULL
1987	NULL
7	NULL
.	NULL

Palmer	NULL
TD	NULL
,	NULL
Hock	NULL
RA	NULL
,	NULL
Osborne	NULL
WR	NULL
,	NULL
Miller	NULL
AD	NULL
:	NULL
Efficient	NULL
retroviral	NULL
mediated	NULL
gene	NULL
transfer	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
ADA	NULL
gene	NULL
in	NULL
diploid	NULL
skin	NULL
fibroblasts	NULL
from	NULL
an	NULL
ADA	NULL
deficient	NULL
patient	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:1055	NULL
,	NULL
1987	NULL
8	NULL
.	NULL

Wilson	NULL
JM	NULL
,	NULL
Birinyi	NULL
LK	NULL
,	NULL
Salomon	NULL
RN	NULL
,	NULL
Libby	NULL
P	NULL
,	NULL
Callow	NULL
AD	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Implantation	NULL
of	NULL
vascular	NULL
grafts	NULL
lined	NULL
with	NULL
genetically	NULL
modified	NULL
endothelial	NULL
cells	NULL
.	NULL

Science	NULL
244:1344	NULL
,	NULL
1989	NULL
9	NULL
.	NULL

Nabel	NULL
EG	NULL
,	NULL
Ploutz	NULL
G	NULL
,	NULL
Boyce	NULL
FM	NULL
,	NULL
Stanley	NULL
JC	NULL
,	NULL
Nabel	NULL
GJ	NULL
:	NULL
Recombinant	NULL
gene	NULL
expression	NULL
in	NULL
vivo	NULL
within	NULL
endothelial	NULL
cells	NULL
of	NULL
the	NULL
arterial	NULL
wall	NULL
.	NULL

Science	NULL
244:1342	NULL
,	NULL
1989	NULL
10	NULL
.	NULL

Wilson	NULL
JM	NULL
,	NULL
Johnston	NULL
DE	NULL
,	NULL
Jefferson	NULL
DM	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Correction	NULL
of	NULL
the	NULL
genetic	NULL
defect	NULL
of	NULL
hepatocytes	NULL
from	NULL
the	NULL
Watanabe	NULL
heritable	NULL
hyperlipidemic	NULL
rabbit	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85:4421	NULL
,	NULL
1988	NULL
11	NULL
.	NULL

Uchida	NULL
N	NULL
,	NULL
Cone	NULL
RD	NULL
,	NULL
Freeman	NULL
GJ	NULL
,	NULL
Mulligan	NULL
RC	NULL
,	NULL
Cantor	NULL
H	NULL
:	NULL
High	NULL
efficiency	NULL
gene	NULL
transfer	NULL
into	NULL
murine	NULL
T	NULL
cell	NULL
clones	NULL
using	NULL
a	NULL
retroviral	NULL
vector	NULL
.	NULL

J	NULL
Immunol	NULL
136:1876	NULL
,	NULL
1986	NULL
12	NULL
.	NULL

Yamoda	NULL
G	NULL
,	NULL
Kitamura	NULL
Y	NULL
,	NULL
Sonoda	NULL
H	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Taki	NULL
S	NULL
,	NULL
Mulligan	NULL
RC	NULL
,	NULL
Osawa	NULL
H	NULL
,	NULL
Diamanstein	NULL
T	NULL
,	NULL
Yokoyama	NULL
S	NULL
,	NULL
Tanguichi	NULL
T	NULL
:	NULL
Retroviral	NULL
expression	NULL
of	NULL
human	NULL
IL-2	NULL
in	NULL
murine	NULL
T-cell	NULL
lines	NULL
results	NULL
in	NULL
cell	NULL
growth	NULL
autonomy	NULL
and	NULL
tumorigenicity	NULL
.	NULL

EMBO	NULL
J	NULL
6:2705	NULL
,	NULL
1987	NULL
13	NULL
.	NULL

Strair	NULL
RK	NULL
,	NULL
Miller	NULL
JS	NULL
,	NULL
Roberts	NULL
BE	NULL
:	NULL
Use	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
to	NULL
study	NULL
the	NULL
regulation	NULL
of	NULL
stably	NULL
integrated	NULL
adenovirus	NULL
early	NULL
promoters	NULL
.	NULL

J	NULL
Virol	NULL
62:2143	NULL
,	NULL
1988	NULL
14	NULL
.	NULL

Feldman	NULL
LT	NULL
,	NULL
Imperiale	NULL
MF	NULL
,	NULL
Nevins	NULL
JR	NULL
:	NULL
Activation	NULL
of	NULL
early	NULL
adenovirus	NULL
transcription	NULL
by	NULL
herpes	NULL
virus	NULL
immediate	NULL
early	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
79:4952	NULL
,	NULL
1982	NULL
15	NULL
.	NULL

Chen	NULL
IS	NULL
,	NULL
Cann	NULL
AJ	NULL
,	NULL
Shah	NULL
NP	NULL
,	NULL
Gaynor	NULL
RB	NULL
:	NULL
Functional	NULL
relation	NULL
between	NULL
HTLV	NULL
II	NULL
x	NULL
and	NULL
adenovirus	NULL
Ela	NULL
proteins	NULL
in	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
230:570	NULL
,	NULL
1985	NULL
16	NULL
.	NULL

Phelps	NULL
WC	NULL
,	NULL
Yee	NULL
CL	NULL
,	NULL
Munger	NULL
K	NULL
,	NULL
Howley	NULL
PM	NULL
:	NULL
;	NULL
Human	NULL
papilloma	NULL
virus	NULL
type	NULL
16	NULL
E7	NULL
gene	NULL
encodes	NULL
transactivating	NULL
and	NULL
transforming	NULL
functions	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
Ela	NULL
.	NULL

Cell	NULL
53:539	NULL
,	NULL
1988	NULL
17	NULL
.	NULL

Loeken	NULL
MR	NULL
,	NULL
Khoury	NULL
G	NULL
,	NULL
Brady	NULL
J	NULL
:	NULL
Stimulation	NULL
of	NULL
adenovirus	NULL
E2	NULL
promoters	NULL
by	NULL
SV40	NULL
T	NULL
antigen	NULL
or	NULL
ElA	NULL
occurs	NULL
by	NULL
different	NULL
mechanisms	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
6:2020	NULL
,	NULL
1986	NULL
18	NULL
.	NULL

La	NULL
Thangue	NULL
NB	NULL
,	NULL
Rigby	NULL
PWJ	NULL
:	NULL
An	NULL
adenovirus	NULL
ElA-like	NULL
transcription	NULL
factor	NULL
is	NULL
regulated	NULL
during	NULL
the	NULL
differentiation	NULL
of	NULL
murine	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
.	NULL

Cell	NULL
49:507	NULL
,	NULL
1987	NULL
19	NULL
.	NULL

Suemori	NULL
H	NULL
,	NULL
Hashimoto	NULL
S	NULL
,	NULL
Nakatsuji	NULL
N	NULL
:	NULL
Presence	NULL
of	NULL
adenovirus	NULL
E1	NULL
Alike	NULL
activity	NULL
in	NULL
preimplantation	NULL
stage	NULL
mouse	NULL
embryos	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
8:3553	NULL
,	NULL
1988	NULL
20	NULL
.	NULL

Strair	NULL
RK	NULL
,	NULL
Towle	NULL
MT	NULL
,	NULL
Smith	NULL
BR	NULL
:	NULL
Recombinant	NULL
retroviruses	NULL
utilizing	NULL
cell	NULL
surface	NULL
antigens	NULL
as	NULL
selectable	NULL
markers	NULL
.	NULL

J	NULL
Virol	NULL
62:4756	NULL
,	NULL
1988	NULL
21	NULL
.	NULL

Guild	NULL
BC	NULL
,	NULL
Finer	NULL
MH	NULL
,	NULL
Housman	NULL
DE	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Development	NULL
of	NULL
retroviral	NULL
vectors	NULL
useful	NULL
for	NULL
gene	NULL
expression	NULL
in	NULL
cultured	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1208	NULL
murine	NULL
embryonal	NULL
cells	NULL
and	NULL
hematopoietic	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Virol	NULL
62:3795	NULL
,	NULL
1988	NULL
22	NULL
.	NULL

Danos	NULL
O	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Safe	NULL
and	NULL
efficient	NULL
generation	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
with	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
host	NULL
ranges	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85:6460	NULL
,	NULL
1988	NULL
23	NULL
.	NULL

Price	NULL
J	NULL
,	NULL
Turner	NULL
D	NULL
,	NULL
Cepko	NULL
C	NULL
:	NULL
Lineage	NULL
analysis	NULL
in	NULL
the	NULL
vertebrate	NULL
nervous	NULL
system	NULL
by	NULL
retrovirus	NULL
mediated	NULL
gene	NULL
transfer	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:156	NULL
,	NULL
1987	NULL
24	NULL
.	NULL

Nolan	NULL
GP	NULL
,	NULL
Fiering	NULL
S	NULL
,	NULL
Nicolas	NULL
J-F	NULL
,	NULL
Herzenberg	NULL
LA	NULL
:	NULL
Fluorescence	NULL
activated	NULL
cell	NULL
analysis	NULL
and	NULL
sorting	NULL
of	NULL
viable	NULL
mammalian	NULL
cells	NULL
based	NULL
upon	NULL
8-D-galactosidase	NULL
activity	NULL
after	NULL
transduction	NULL
of	NULL
E.	NULL
coli	NULL
lac	NULL
Z.	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85:2603	NULL
,	NULL
1988	NULL
25	NULL
.	NULL

Yu	NULL
S-F	NULL
,	NULL
von	NULL
Ruden	NULL
P	NULL
,	NULL
Kantoff	NULL
PW	NULL
,	NULL
Garber	NULL
C	NULL
,	NULL
Seiberg	NULL
M	NULL
,	NULL
STRAIR	NULL
ET	NULL
AL	NULL
Ruther	NULL
U	NULL
,	NULL
Anderson	NULL
WF	NULL
,	NULL
Wagner	NULL
EF	NULL
,	NULL
Gilboa	NULL
E	NULL
:	NULL
Self	NULL
inactivating	NULL
retrovirus	NULL
designed	NULL
for	NULL
the	NULL
transfer	NULL
of	NULL
whole	NULL
genes	NULL
into	NULL
mammalian	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
83:3194	NULL
,	NULL
1986	NULL
26	NULL
.	NULL

Korman	NULL
AJ	NULL
,	NULL
Frantz	NULL
JD	NULL
,	NULL
Strominger	NULL
JL	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Expression	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
antigens	NULL
using	NULL
retroviral	NULL
vectors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:2150	NULL
,	NULL
1987	NULL
27	NULL
.	NULL

Salahuddin	NULL
SZ	NULL
,	NULL
Markham	NULL
PD	NULL
,	NULL
Wong-Staal	NULL
F	NULL
,	NULL
Franchini	NULL
G	NULL
,	NULL
Kalayanaraman	NULL
VS	NULL
,	NULL
Gallo	NULL
RC	NULL
:	NULL
Restricted	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
in	NULL
transformed	NULL
human	NULL
umbilical	NULL
cord	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
129:51	NULL
,	NULL
1983	NULL
28	NULL
.	NULL

Jones	NULL
NC	NULL
,	NULL
Rigby	NULL
PWJ	NULL
,	NULL
Ziff	NULL
EB	NULL
:	NULL
Trans-acting	NULL
protein	NULL
factors	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
eukaryotic	NULL
transcription	NULL
:	NULL
Lessons	NULL
from	NULL
studies	NULL
on	NULL
DNA	NULL
tumor	NULL
viruses	NULL
.	NULL

Genes	NULL
Dev	NULL
2:267	NULL
,	NULL
1988	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

«	NULL
9	NULL
a	NULL
A	NULL
®	NULL
3	NULL
00	NULL
1990	NULL
76	NULL
:	NULL
1201-1208	NULL
Retroviral	NULL
mediated	NULL
transfer	NULL
and	NULL
expression	NULL
of	NULL
exogenous	NULL
genes	NULL
in	NULL
primary	NULL
lymphoid	NULL
cells	NULL
:	NULL
assaying	NULL
for	NULL
a	NULL
viral	NULL
transactivator	NULL
activity	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
cells	NULL
o	NULL
~	NULL
--	NULL
0	NULL
%	NULL
>	NULL
{	NULL
MRI/UV	NULL
s.	NULL
f	NULL
)	NULL
.	NULL

to	NULL
210	NULL
%	NULL
®	NULL
RK	NULL
Strair	NULL
,	NULL
M	NULL
Towle	NULL
,	NULL
PW	NULL
Heald	NULL
and	NULL
BR	NULL
Smith	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/76/6/1201	NULL
.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

